Is Buying 52-Week Stock Like Cerus Corporation (CERS) a Winning Strategy?

March 20, 2018 - By Maria Brooks

Investors sentiment increased to 1.32 in 2017 Q3. Its up 0.02, from 1.3 in 2017Q2. It improved, as 9 investors sold Cerus Corporation shares while 22 reduced holdings. 11 funds opened positions while 30 raised stakes. 57.26 million shares or 0.28% less from 57.42 million shares in 2017Q2 were reported.
Citadel Limited Liability Company invested in 933,089 shares or 0% of the stock. Moreover, Credit Suisse Ag has 0% invested in Cerus Corporation (NASDAQ:CERS). Elk Creek Prtn Ltd Liability Corp invested in 6.13 million shares or 1.05% of the stock. Salzhauer Michael holds 0.43% or 363,639 shares. Susquehanna Interest Grp Llp invested 0% in Cerus Corporation (NASDAQ:CERS). Financial Bank Of New York Mellon Corp reported 457,493 shares. Cubist Systematic Strategies Ltd has 28,296 shares. Northern Trust Corporation invested in 1.28M shares. Voya Invest Management Llc invested 0% of its portfolio in Cerus Corporation (NASDAQ:CERS). 8.34M are owned by Blackrock. Baker Bros Advisors Lp has 0.22% invested in Cerus Corporation (NASDAQ:CERS) for 9.75M shares. Tiaa Cref Investment Mngmt Ltd Liability Corporation reported 356,854 shares. Premier Asset Ltd Liability Company, a Illinois-based fund reported 127,487 shares. Amalgamated Bancorporation reported 12,928 shares. Great West Life Assurance Can holds 0% of its portfolio in Cerus Corporation (NASDAQ:CERS) for 8,200 shares.

Since March 10, 2018, it had 1 insider purchase, and 5 sales for $597,723 activity. 17,766 shares valued at $87,795 were sold by Greenman William Mariner on Saturday, March 10. 3,680 shares were sold by Benjamin Richard J, worth $18,328 on Saturday, March 10. Another trade for 4,686 shares valued at $23,151 was sold by Moore Carol. Menard Chrystal sold $22,793 worth of stock. $23,409 worth of Cerus Corporation (NASDAQ:CERS) shares were sold by Green Kevin Dennis.

The stock of Cerus Corporation (NASDAQ:CERS) hit a new 52-week high and has $6.18 target or 7.00 % above today’s $5.78 share price. The 6 months bullish chart indicates low risk for the $748.42 million company. The 1-year high was reported on Mar, 20 by If the $6.18 price target is reached, the company will be worth $52.39M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 5.58% or $0.31 during the last trading session, reaching $5.78. About 729,672 shares traded. Cerus Corporation (NASDAQ:CERS) has declined 40.83% since March 20, 2017 and is downtrending. It has underperformed by 57.53% the S&P500.

Analysts await Cerus Corporation (NASDAQ:CERS) to report earnings on May, 2. They expect $-0.12 earnings per share, up 33.33 % or $0.06 from last year’s $-0.18 per share. After $-0.10 actual earnings per share reported by Cerus Corporation for the previous quarter, Wall Street now forecasts 20.00 % negative EPS growth.

Cerus Corporation (NASDAQ:CERS) Ratings Coverage

Among 5 analysts covering Cerus (NASDAQ:CERS), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Cerus has $8 highest and $4.0 lowest target. $5.75’s average target is -0.52% below currents $5.78 stock price. Cerus had 11 analyst reports since August 11, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Tuesday, August 11 by Zacks. The firm earned “Buy” rating on Wednesday, August 19 by BTIG Research. The company was maintained on Wednesday, June 7 by Cantor Fitzgerald. The rating was maintained by Cantor Fitzgerald on Thursday, March 8 with “Buy”. The rating was maintained by Cowen & Co on Thursday, October 5 with “Buy”. The firm has “Buy” rating given on Wednesday, January 24 by Robert W. Baird. The rating was maintained by Robert W. Baird on Monday, October 30 with “Buy”. Cantor Fitzgerald maintained the stock with “Buy” rating in Monday, January 8 report. The firm earned “Buy” rating on Thursday, November 30 by Robert W. Baird. The rating was downgraded by Wedbush on Thursday, December 17 to “Neutral”.

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company has market cap of $748.42 million. The Company’s INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. It currently has negative earnings. The company's INTERCEPT Blood Systems for platelets and plasma are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: